Toggle menu

NOVEL Study

Start date:
April 2019
End date:
April 2020
Co-ordinated by:
LumiraDx
Main trial site:
Royal Infirmary Edinburgh

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Primary Objective: evaluation of diagnostic platform with biomarkers useful in emergency settings.

Sample: Patients over 18 years old presenting to the Emergency Department with mainly symptoms of cardiovascular conditions.

Trial Design: Prospective observational (cohort) feasibility study

Chief Investigator

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Caroline Blackstock

AMU Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

Rachel O'Brien

Lead Research Nurse

Sian Dalgleish

Senior Research Nurse

Fiona McCurrach

Senior Research Nurse

Alison Williams

Senior Research Nurse

Clare Moceivei

Senior Research Nurse

More EMERGE Trials

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Read more

NOVEL Study

Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)